Axis Imaging The Script
The Script · Published by Axis Imaging, Melbourne

Thursday 12 November 2026

3 stories today

1. Australia's pregabalin use and overdoses have fallen since 2018, BMJ finds

Australia managed something the UK hasn't. Pregabalin overdoses here are heading down, with poison centre calls 47% below where the old trend line said they'd be.

The BMJ study tracked dispensing claims and poison centre data from 2016 to 2024: 3,441,851 scripts to 227,864 people, plus 4,871 overdose calls. Use and overdose both peaked in 2018, then dispensing dropped at three points. The first was December 2018, after the media coverage of harms. The second was May 2020, a month after tighter prescribing restrictions. The third was December 2021, following the February 2021 boxed warnings and the rollout of real-time prescription monitoring.

By December 2021, dispensing was 25% below the projected trend, roughly 118,390 fewer scripts that month, and it was still falling 0.7% a month. Overdose calls were sliding 1.6% a month. Compare the UK, where a gabapentinoid shows up in one-third of substance use deaths and those deaths more than doubled between 2018 and 2022.

The authors are upfront that this is observational, so it shows the timing lined up rather than proving cause. They only counted subsidised scripts, and they couldn't see whether patients lost access to pain treatment or switched to opioids. They also say dispensing still far outstrips what approved indications alone would justify.

In the linked editorial, Professor David Juurlink says pregabalin should be reserved for proven conditions like diabetic nerve pain and fibromyalgia, and avoided for low back pain and sciatica. "Persisting with ineffective treatment or escalating the dose in pursuit of relief that has yet to materialize is more than misplaced optimism. It is an invitation to harm," he writes.

The takeaway: Next time a patient on pregabalin for back pain or sciatica asks "do I still need these tablets?", treat it as an invitation to review rather than a quick renewal. If there's no meaningful benefit, that's your answer.

Read the source

2. Older adults should skip the morning blood pressure dose before surgery

Swap an older patient's morning ACE inhibitor for a sugar pill and treated low blood pressure during surgery drops from 45.5% to 31.2%. That's roughly one in seven patients spared a hypotensive dip, achieved by doing less.

The BMJ trial randomised 2,012 adults aged 60 to 80 (average 69) with hypertension who'd been on an ACE inhibitor or ARB for an average of 10 years. All were having noncardiac surgery under general anaesthetic at five large Chinese hospitals between November 2020 and December 2023. Half took their usual tablet on surgery morning and half took an identical placebo, so neither patients nor anaesthetists knew who'd skipped.

Hypotension meant a mean pressure under 65 mmHg, or a drop of at least 30% from baseline, that needed treatment. The placebo group also needed vasopressors less often (28.5% vs 41.1%) and spent 1.3 fewer minutes hypotensive on average.

The hard outcomes didn't move. Postoperative hypotension, 30-day complications and death were no different between groups. So you get a smoother anaesthetic, but no proven survival win yet.

This is overseas evidence from older Chinese patients having moderate-length surgery, with follow-up only to 30 days. The researchers flag that very high-risk operations and other populations weren't tested. They still call it "high-certainty evidence" and expect it to inform international guidelines, which until now have offered only weak recommendations.

For GPs, this is the question every pre-op patient asks: "Do I take my tablets that morning?" For ACE inhibitors and ARBs in over-60s, there's now a blinded trial answer. Beta blockers and other classes weren't studied, so this doesn't cover them.

The takeaway: When an older patient on an ACE inhibitor or ARB is booked for noncardiac surgery, the evidence backs skipping the morning dose. Check that matches the anaesthetist's pre-op instructions so the patient doesn't get two different answers.

Read the source

3. RACGP wants clarity on Heart Foundation's draft hypertension guidelines

The Heart Foundation's draft hypertension guideline calls 120-139/80-89 mmHg a single category of elevated blood pressure. Elsewhere it splits that same range into two treatment bands. The RACGP noticed.

This is the first major update to the Australian hypertension guideline since 2016, and the college backs it overall. Its consultation submission still lands eight recommendations asking for "clarity, consistency and clinical utility".

Top of the list is urine protein. The draft starts with dipstick testing before moving to urine albumin-creatinine ratio. The college questions that order, since ACR is generally more sensitive and picks up albuminuria a dipstick misses.

Then there's drug therapy. The 2023 CVD risk guideline set no BP thresholds for starting treatment, so the RACGP wants this one to spell out when to consider or start pharmacotherapy for each five-year risk category. That includes what to do when systolic and diastolic point in different directions. Professor Rowena Ivers says registrars and IMGs will follow this guideline too, so the clarity matters.

The draft is heading towards screening for primary aldosteronism at diagnosis, lower treatment thresholds, upfront combination therapy, faster up-titration and automated office BP with validated upper-arm devices. The college accepts the evidence but warns this means "substantial" change management, possibly including new equipment and dedicated space. It also wants more on long-term monitoring, the part GPs actually do, and sharper equity guidance than advice to be "individualised", which the college points out applies to most patients.

Expect the Red Book to need updating once the final version lands.

The takeaway: Nothing changes yet. The draft isn't public and the final guideline is due in early 2027. In the meantime, check whether your practice has a validated upper-arm automated BP device, because that's where the guideline is heading.

Read the source

Also noted

Get tomorrow's issue by email at 6:30am.